How Much Does Wegovy Cost?

Summary: Wegovy's list price is $1,349 per month, but almost nobody pays that. With commercial insurance the savings card brings it to $25 a month, NovoCare cash pay starts at $199 and settles at $349, and Medicare only covers it under a narrow heart-disease carve-out.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: Wegovy's list price is $1,349 per month for a 28-day supply of four pens, regardless of which dose strength you are on ^[1]. Almost nobody actually pays that. With commercial insurance and the Wegovy Savings Offer the price drops to $25 per month. Without insurance, Novo Nordisk's NovoCare cash-pay program starts at $199 per month for the first two fills and then settles at $349 per month for the standard 2.4 mg maintenance dose ^[2].

What you pay depends on three things: whether your insurance has Wegovy on its formulary, whether you are on commercial or government coverage, and whether you are willing to enroll directly with the manufacturer's pharmacy. The full price ladder is below.

The Wegovy list price in 2026

$1,349 per month. One box of four pens. Same price at every dose strength, from the 0.25 mg starter pen up through the 2.4 mg maintenance pen ^[1]. That is roughly $16,188 per year if you pay sticker price with no insurance, no savings card, and no manufacturer program.

Novo Nordisk uses flat pricing across all injectable doses on purpose. The titration schedule moves you from 0.25 mg to 0.5 mg to 1 mg to 1.7 mg to 2.4 mg over about four months. A patient who has to pay more for higher doses might stall out at a sub-therapeutic dose to save money. Flat pricing keeps the cost structure neutral on dose escalation.

Wegovy HD, the 7.2 mg higher-dose pen launched for patients who plateau on 2.4 mg, lists at the same $1,349. The NovoCare cash-pay program prices it separately at $399 per month ^[2].

With commercial insurance: the $25 savings card

If you have commercial insurance (employer plan, ACA marketplace plan, COBRA) and your plan covers Wegovy, the Wegovy Savings Offer brings your copay down to as little as $25 per month ^[1][2].

Here is how the math works. The card pays up to $100 per one-month fill toward your copay. If your plan's specialty-tier copay is $125, the card knocks $100 off, you pay $25. If your copay is $75, the card pays $50 and you still pay $25. If your copay is $300, the card pays the maximum $100 and you pay $200. The $25 minimum is the floor; the $100 monthly cap is the ceiling.

The terms changed on January 2, 2026. The previous version of the card had a $225 maximum and a $0 minimum copay, so some patients did get Wegovy free. Under the current rules the floor is $25 and the ceiling is $100 in savings per fill ^[2]. Enrollment is free at novocare.com.

Who the savings card excludes

Federal anti-kickback law bars manufacturer copay cards from being used by anyone on government insurance. That means Medicare, Medicaid, TRICARE, the VA, and Indian Health Service patients cannot use the Wegovy Savings Offer. This is not Novo Nordisk's choice. It is statute.

If you are on Medicare or Medicaid, skip the savings card section entirely. The path for you is different and lives further down this page.

Without insurance: NovoCare cash pay

For uninsured patients, or for patients whose insurance refuses to cover Wegovy, Novo Nordisk runs its own direct-to-patient pharmacy called NovoCare Pharmacy (dispensed through CoAssist). Cash-pay pricing for the injectable in 2026:

The intro $199 price is for patients new to NovoCare and only applies to the 0.25 mg and 0.5 mg starter doses, for two fills, through June 30, 2026 ^[2]. After that two-month window, or as soon as you titrate up to 1 mg or higher, the price becomes $349.

So a realistic first-year cash-pay total looks like: $199 + $199 + ten months at $349 = $3,888 per year for someone who titrates on schedule. That is roughly a 76 percent discount versus list price, available without insurance, without a coupon, and without income verification. You just need a valid prescription and a NovoCare account.

Oral Wegovy as a cheaper alternative

Wegovy is also available as a tablet (oral semaglutide marketed under the Wegovy brand for weight loss, approved by the FDA in December 2025). The cash-pay price is $149 per month for the 1.5 mg or 4 mg dose and $299 per month for the 9 mg or 25 mg maintenance dose ^[1]. The 4 mg promotional price runs through August 31, 2026, then moves to $199.

For pure cost, oral Wegovy is the cheapest legal way to take semaglutide for weight loss in 2026, at the maintenance dose, with no insurance involvement at all.

What about GoodRx, coupons, and other discount cards?

You will see search results promising "up to 70% off Wegovy with GoodRx." Read those carefully. GoodRx does not have a meaningful discount on Wegovy. The headline number reflects the savings versus pharmacy walk-up cash prices that hover around $1,400 to $1,800 per month, not the list price, and not anything you would actually pay if you used the manufacturer programs above.

For Wegovy specifically, the manufacturer programs (Savings Offer for insured patients, NovoCare cash pay for uninsured) consistently beat third-party discount cards. There is no GoodRx-Wegovy coupon that gets you below $349 per month for the maintenance dose. If a website is showing one, check the fine print. It is usually GoodRx's price for compounded semaglutide from a telehealth partner, which is not the same product.

Medicare coverage: only for the heart-disease indication

Standard Medicare Part D plans do not cover weight-loss drugs. That has been the rule since Part D was created in 2003. Wegovy was excluded from Medicare on cost grounds for its entire pre-2024 history.

That changed in March 2024 when the FDA approved a new indication for Wegovy based on the SELECT trial, which showed a 20 percent reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with overweight or obesity and pre-existing cardiovascular disease, without diabetes ^[3]. The indication is cardiovascular risk reduction, not weight loss.

CMS subsequently confirmed that Medicare Part D plans may cover Wegovy when prescribed for cardiovascular risk reduction in eligible patients ^[4]. "May" is doing work in that sentence. Each Part D plan decides whether to add Wegovy to its formulary for the cardiovascular indication, and most have done so on a specialty tier with prior authorization requirements.

The practical filter on Medicare coverage looks like this:

• You must have established cardiovascular disease (prior heart attack, prior stroke, or symptomatic peripheral artery disease).
• You must have overweight (BMI 27 to 29.9) or obesity (BMI 30+).
• Your prescriber must document the cardiovascular indication, not "for weight loss."
• The plan's prior authorization will check all three.

If you qualify, copays vary by plan but tend to land in the $50 to $200 per month range on specialty tiers. If you do not qualify, Medicare will pay nothing toward Wegovy, you cannot use the manufacturer savings card to fill the gap, and your only option is NovoCare cash pay.

Medicaid coverage varies wildly by state

Medicaid is a federal-state program. Each state's Medicaid program decides separately whether to cover weight-loss drugs. As of 2026, a minority of state Medicaid programs cover Wegovy for obesity, more cover it for the cardiovascular indication after the 2024 label expansion, and some still refuse coverage entirely.

States that have expanded Medicaid coverage for GLP-1 weight-loss drugs include Pennsylvania, Michigan, Massachusetts, North Carolina, and Virginia, among others. States with the most restrictive coverage tend to be the ones with the tightest Medicaid budgets. Coverage rules can change year to year as state budgets reset.

The fastest way to know: call your state Medicaid plan and ask whether Wegovy is on the formulary, and whether it requires prior authorization. Do not assume your neighbor's state-Medicaid coverage matches yours.

Medicaid patients cannot use the Wegovy Savings Offer, but they can apply to the Novo Nordisk Patient Assistance Program (PAP) if their income is at or below 400 percent of the federal poverty level (about $62,400 for an individual in 2026) and they are otherwise uninsured for the medication.

The prior authorization reality

Even with commercial insurance and Wegovy on your formulary, the prior authorization step is where many prescriptions die. Insurers commonly require:

• BMI documentation (usually 30+ for obesity, or 27+ with a comorbidity like hypertension, sleep apnea, dyslipidemia, or type 2 diabetes)
• Documented attempt at lifestyle modification, sometimes with a structured program (medically supervised diet, behavioral counseling)
• "Step therapy" requiring you to fail a cheaper alternative first (older anti-obesity drugs, or sometimes the cheaper oral option)
• Periodic renewal showing 5 percent weight loss within 3 to 6 months

About half of first-attempt GLP-1 prescriptions get denied at this stage. Most denials are appealable, and over 80 percent of properly documented appeals succeed at the second or third level. If your plan denies you, do not assume that is final. Ask your prescriber's office for the denial letter, get the specific reason cited, and respond with the documentation they want.

Compounded semaglutide: cheaper, but the legal window mostly closed

During the 2022 to 2024 Wegovy shortage, the FDA placed semaglutide on its drug shortage list, which legally permitted 503A and 503B compounding pharmacies to make and ship compounded semaglutide. Cash prices through telehealth platforms ran $150 to $300 per month, far below the Wegovy list price, and millions of patients filled their prescriptions through compounders rather than through Novo Nordisk.

That window largely closed in early 2025. The FDA removed semaglutide from the shortage list in February 2025 after Novo Nordisk reported that supply met demand. Once a drug is off the shortage list, the FDA's enforcement discretion for compounding it disappears. 503A pharmacies must stop compounding the drug for general use. 503B outsourcing facilities have a tighter timeline and stricter rules.

A narrow exception exists for compounded semaglutide that is clinically different from the FDA-approved product, for example a different dose strength, a different route of administration, or a documented intolerance to an inactive ingredient in Wegovy. These exceptions are real but narrow. Most patients who were getting $200-per-month compounded semaglutide through telehealth in 2024 are now paying NovoCare or a similar cash-pay program in 2026.

What Wegovy costs in the UK

For comparison, in the UK Wegovy is available through the NHS in narrow circumstances (BMI 35+ with at least one weight-related comorbidity, referred through a specialist weight-management service) at standard NHS prescription charges, currently £9.90 per prescription in England, free in Scotland, Wales, and Northern Ireland.

Privately in the UK, Wegovy runs roughly £175 to £300 per month depending on the dose and the provider (Boots, LloydsDirect, and private clinics all sell it). That is about $220 to $380 per month in current dollars, which is broadly comparable to the US NovoCare cash-pay price. UK pricing reflects a single negotiated price between Novo Nordisk and the NHS, with private providers marking up from there.

The cheapest legal path, decision tree

The right answer depends on your insurance situation. In order:

1. Do you have commercial insurance that lists Wegovy as covered? Enroll in the Wegovy Savings Offer. Your monthly cost is $25. This is the cheapest path and there is no income limit.
2. Commercial insurance that requires prior auth? File the prior auth with full BMI and comorbidity documentation. If approved, $25 with the savings card. If denied, appeal. Use NovoCare cash pay ($199 to $349) while the appeal is in motion.
3. Commercial insurance that excludes Wegovy entirely? Either appeal for an exception, switch to NovoCare cash pay, or consider oral Wegovy ($149 to $299 per month).
4. Medicare with established cardiovascular disease and BMI 27+? Ask your prescriber to write the prescription for cardiovascular risk reduction, not weight loss. Submit prior auth to your Part D plan. Expected copay $50 to $200 per month.
5. Medicare without cardiovascular disease, or Medicaid in a non-covering state? No insurance pathway. Use NovoCare cash pay or apply to the Novo Nordisk Patient Assistance Program if you are under 400 percent FPL.
6. Uninsured, under 400 percent FPL? Apply to the Novo Nordisk PAP first. If approved, the drug is free or near-free. If denied, fall back to NovoCare cash pay.
7. Uninsured, above 400 percent FPL? NovoCare cash pay is your floor. $199 per month for the first two fills at the starter doses, $349 per month thereafter for the injectable, or $149 to $299 per month for the oral tablet.

Common questions about Wegovy cost

How much does Wegovy cost without insurance in 2026?

Through Novo Nordisk's NovoCare Pharmacy, $199 per month for the first two fills (0.25 mg or 0.5 mg starter), then $349 per month for the 1 mg through 2.4 mg doses. Walk-in pharmacy cash prices without NovoCare run closer to the $1,349 list price.

What is the Wegovy list price?

$1,349 per month for a 28-day supply of four pens, the same price at every dose strength from 0.25 mg to 2.4 mg. Wegovy HD 7.2 mg also lists at $1,349.

How do I get Wegovy for $25 a month?

Have commercial insurance that covers Wegovy on its formulary, enroll in the free Wegovy Savings Offer at novocare.com, and present the card at your pharmacy. The card pays up to $100 toward your copay, with a $25 minimum.

Can I get Wegovy for $25 if I have Medicare?

No. Federal law prohibits manufacturer copay cards from being used by anyone on Medicare, Medicaid, TRICARE, or the VA. Medicare may cover Wegovy directly for patients with established cardiovascular disease, at a typical Part D copay of $50 to $200 per month.

Does Medicare cover Wegovy for weight loss?

No. Medicare Part D does not cover weight-loss drugs by statute. Medicare may cover Wegovy under a separate indication (cardiovascular risk reduction in adults with overweight or obesity and existing heart disease) added in 2024 after the SELECT trial.

Does Medicaid cover Wegovy?

Coverage varies by state. A growing number of state Medicaid programs cover Wegovy for obesity, more cover it for the cardiovascular indication, and some refuse coverage. Call your state Medicaid plan to confirm.

How much does the Wegovy savings card save you?

Up to $100 per one-month fill, up to $200 on a two-month fill, up to $300 on a three-month fill. Your final price floors at $25 per month. Commercial insurance is required.

Is there a Wegovy patient assistance program?

Yes. The Novo Nordisk Patient Assistance Program may provide Wegovy at no cost to patients who are uninsured, US residents, prescribed Wegovy by a licensed provider, and earning at or below 400 percent of the federal poverty level (roughly $62,400 for an individual in 2026).

Why is Wegovy so expensive in the US compared to the UK?

The UK NHS negotiates a single national price for the drug. The US has no equivalent negotiator for most patients, so Novo Nordisk sets a list price and then offers programs to bring it down for specific groups. NovoCare cash pay at $349 per month is broadly comparable to UK private pricing.

Is compounded semaglutide still cheaper than Wegovy?

Sometimes, but the legal pathway narrowed significantly when the FDA declared the Wegovy shortage resolved in February 2025. Compounded semaglutide is now restricted to specific clinical exceptions (different dose, intolerance to an inactive ingredient). Most patients who were paying $200 per month through telehealth in 2024 are no longer eligible for compounded versions in 2026.

Does Wegovy cost the same at every dose?

At list price and through commercial insurance, yes. Through NovoCare cash pay, no. The intro $199 price is only for the 0.25 mg and 0.5 mg doses for the first two months. Every other dose, and every fill after month two, is $349 for the injectable.

What is the cheapest way to get Wegovy in 2026?

For commercially insured patients: the $25 savings card. For uninsured patients above the PAP income limit: oral Wegovy at $149 per month for the starter dose. For uninsured patients below 400 percent FPL: the Novo Nordisk PAP, which can be $0.

What this article does not cover

This page is the cost picture for Wegovy specifically. Coverage rules for Ozempic (same molecule, semaglutide, but FDA-approved for type 2 diabetes rather than weight loss) work differently, and Medicare actually does cover Ozempic for its on-label indication. If you have type 2 diabetes plus obesity, ask your prescriber whether Ozempic is a covered path that lands you on semaglutide at a lower cost. The dosing and the trial data are not identical to Wegovy, so this is a clinical decision, not just a financial one. See the FDA prescribing information for both products if you need to compare them directly ^[5].